← Back to Search

Anti-Vaping Messages for Reducing Nicotine Use in Young Adults

N/A

Recruiting

Research Sponsored by University of Georgia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will test if anti-vaping PSAs can reduce nicotine use in young adult vapers; participants will receive weekly online surveys, view PSAs, and be biochemically tested.

Who is the study for?

This trial is for young adult vapers who haven't smoked cigarettes in the past month, have used e-cigarettes on at least 3 days in that time, and can safely undergo MRI scans. It's not for those with recent cigarette use, major health disorders, or MRI contraindications.

What is being tested?

The study tests how anti-vaping messages affect young vapers' brains and behavior over a year. Participants will see regular or flavor-specific anti-vaping PSAs while their brain activity is monitored using fMRI. They'll switch message types after 6 months.

What are the potential side effects?

There are no direct side effects from the interventions since they involve exposure to public service announcements and surveys. However, undergoing an fMRI may include discomfort from staying still in a confined space.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Carbon monoxide

Self-report monthly smoking severity

Self-report monthly vaping severity

+1 more

Secondary study objectives

Cigarette smoking urge

Electronic cigarette user

Message effectiveness perceptions

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: No message exposure (control condition)Experimental Treatment1 Intervention

Participants will not be receiving any PSA exposure over the 12 months.

Group II: Message exposure (sequence: regular PSAs then flavor PSAs)Experimental Treatment1 Intervention

Participants randomly assigned to this arm will receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the first 6 months of the study, and will then receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the second 6 months of the study.

Group III: Message exposure (sequence: flavor PSAs then regular PSAs)Experimental Treatment1 Intervention

Participants randomly assigned to this arm will receive weekly emails and text messages of flavor PSAs (i.e., focused specifically on harms and negative consequences associated with vaping flavored e-cigarette products) for the first 6 months of the study, and will then receive weekly emails and text messages of regular PSAs (i.e., focused in general on the negative consequences of vaping) for the second 6 months of the study.

Do I qualify?Apply below to find out